Trial reportScientific reports2026
Vitamin D in the prevention of left ventricular remodelling after an acute myocardial infarction: a randomized clinical trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02548364 (Multicentric, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicentric, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
No clinical trial has yet assessed the effect of vitamin D on patients experiencing ST-segment elevation myocardial infarction (STEMI). In this multicentre, randomised (2:1), double-blind, placebo-controlled trial, 93 patients with anterior STEMI were randomised to calcifediol or placebo, for 12 months. The primary endpoint was left ventricular remodelling, defined as a 15% increase in left ventricular end-diastolic volume (EDV) on magnetic resonance imaging. Sixty-five patients were allocated to calcifediol and 28 to placebo. Calcidiol levels increased in the intervention group (20.0[8.4, 36.5] vs. 2.0[− 0.3, 4.5] ng/mL, p < 0.001). No differences were observed in the incidence of left ventricular remodelling (26.2% vs. 21.4%; p = 0.824) and in these secondary end points: increment in end-diastolic volume (6.0[− 6.5, 21.6] vs. 6.1[− 8.1, 23.8] mL; p = 0.773), end-systolic volume (− 6.9[− 15.9, 4.5] vs. 1.3[− 20.9, 17.2] mL; p = 0.908), ejection fraction (5.1[2.1, 10.0] vs. 7.7[− 0.9, 11.0]%; p = 0.992), and in plasma levels of N-terminal pro-brain natriuretic peptide, galectin-3, ST2, growth differentiation factor-15, fibroblast growth factor-23 (FGF23), high-sensitivity C-reactive protein, and monocyte chemoattractant protein-1. Similar results were observed in patients with baseline FGF23 above the median, in those with calcidiol < 30 ng/mL, and in the subgroup with ejection fraction ≤ 40%. In conclusion, calcifediol does not improve left ventricular remodelling or affect biomarkers related to heart failure and inflammation following a STEMI.Trial registration: NCT02548364. https://clinicaltrials.gov/study/NCT02548364?term=VITDAMI%20Vitamin%20D%20in%20acute%20myocardial%20infarction&rank=1 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.